WhaleCreep

Which hedge funds own AIMT? AIMMUNE THERAPEUTICS INC, Q2 2026 13F holders

0 tracked hedge funds disclosed a position in AIMT (AIMMUNE THERAPEUTICS INC) in their Q2 2026 13F filings, worth $0 in total.

0
Holders
0
New this quarter
0
Exited this quarter
$0
Combined value
–
Share of managers holding

Holders, Q2 2026

0 rows

Ownership over time

By quarter
QuarterHoldersManagers filingShare holdingCombined value
Q4 20200710.0%$0
Q3 20202682.9%$120m
Q2 20201681.5%$12.9m
Q1 20203684.4%$29.7m
Q4 20190670.0%$0
Q3 20192603.3%$13.2m
Q2 20191601.7%$10.8m
Q1 20190600.0%$0
Q4 20181601.7%$14.7m
Q3 20182593.4%$11.2m
Q2 20182593.4%$47.0m
Q1 20181591.7%$34.4m
Q4 20172593.4%$47.2m
Q3 20172563.6%$27.6m
Q2 20171561.8%$20.5m
Q1 20171561.8%$14.8m
Q4 20163565.4%$24.3m
Q3 20161521.9%$19.4m
Q2 20162523.8%$14.1m
Q1 20161521.9%$17.5m
Q4 20151521.9%$14.6m
Q3 20151521.9%$20.0m

Who discovered AIMT first?

Earliest meaningful positions among the 6 tracked managers seen opening AIMT since Q3 2015.

1 rows
RA Capital Management, L.P.Q3 20152.9%2.9%6Exited by Q1 2017−19%

Stock since is the split-adjusted change in the quarter-end price, excluding dividends, from the first reported quarter: the price the 13F filings themselves imply (value ÷ shares), blank across any gap that cannot be accounted for. It describes the stock, not the return any manager earned.